Promising blood cancer trial pulled before starting
NCT ID NCT06297629
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study was designed to see if the drug ASTX727, taken alone or with donor immune cells, could help control blood cancers that return or persist after a stem cell transplant. It was planned for adults aged 18 to 75 with certain types of leukemia or myelodysplastic syndrome. However, the trial was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.